Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company, announced on Friday that it has received the 'No Action Indicated' classification subsequent to a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance programme.
The PADE programme intends to shield patients from poor quality, unsafe, and ineffective dugs via proactive compliance strategies and risk-based enforcement actions. The main aim of the programme is to ensure that accurate, reliable, and timely safety data is submitted to the FDA in compliance with postmarking laws and regulations.
The two and a half-day inspection by two FDA Consumer Safety Officers revealed no objectional condition or practice in the six years that Endari has been marketed and so awarded a 'No Action Indicated' (NAI) inspection classification.
Charles Stark, Pharm.D., chief scientific officer of Emmaus Life Sciences, Inc, said, 'Based on the 2019 FDA inspection results survey, this places Emmaus within the top 16% of all companies investigated in 2019. This exemplifies Emmaus' mission to provide the highest quality Endari(R) (L-glutamine oral powder) and monitor its safety for our patients living with Sickle Cell Disease. These outcomes were possible due to the consistent and dedicated compliance to FDA regulations around surveillance, receipt, evaluation, and timely reporting of safety data by the Safety and Regulatory colleagues at Emmaus (Rafael Razon, M.D. and Rajani Singh). In addition, Emmaus is grateful to APCER Life Sciences, our long-standing Pharmacovigilance business partner, for their continued support.'
Pykus Therapeutics' PYK-2101 achieves positive interim clinical trial results
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
SKNV launches Kefunova Cream for actinic keratosis and superficial basal cell carcinoma
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
MHRA to review monthly maintenance dosing for Leqembi in early Alzheimer's treatment
Ro integrates with NovoCare Pharmacy to offer access to all doses of Wegovy at lowest price
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
CSL Vifor and Travere Therapeutics gain full EU approval for FILSPARI in IgA nephropathy